HC Wainwright Issues Negative Outlook for Precigen Earnings

Key Points

• HC Wainwright revised its Q3 2025 earnings estimate for Precigen, projecting a loss of ($0.09) per share, down from the previous estimate of ($0.07).
• Despite the negative outlook, HC Wainwright maintains a "Buy" rating for Precigen with a target price of $6.00.
• Precigen's most recent earnings report showed a loss of ($0.11) per share, which was better than analysts' expectations of ($0.14) per share.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Stock analysts at HC Wainwright dropped their Q3 2025 EPS estimates for Precigen in a note issued to investors on Wednesday, August 13th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn ($0.09) per share for the quarter, down from their prior estimate of ($0.07). HC Wainwright has a "Buy" rating and a $6.00 price objective on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen's Q4 2025 earnings at ($0.05) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.06) EPS.

Precigen (NASDAQ:PGEN - Get Free Report) last released its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.86 million for the quarter, compared to analysts' expectations of $0.67 million. Precigen had a negative return on equity of 842.83% and a negative net margin of 2,868.66%.

Several other research analysts have also recently issued reports on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Precigen in a report on Thursday, May 15th. Wall Street Zen upgraded shares of Precigen from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. JMP Securities reaffirmed a "market outperform" rating and issued a $6.00 price objective on shares of Precigen in a research report on Thursday, June 12th. Finally, JPMorgan Chase & Co. raised Precigen from an "underweight" rating to a "neutral" rating in a report on Friday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $6.00.

Precigen Price Performance

Shares of Precigen stock opened at $1.85 on Friday. Precigen has a 1 year low of $0.65 and a 1 year high of $2.17. The firm's 50-day moving average is $1.65 and its 200 day moving average is $1.58. The stock has a market cap of $551.24 million, a price-to-earnings ratio of -4.40 and a beta of 1.87.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new stake in Precigen in the 4th quarter worth approximately $27,000. Envestnet Asset Management Inc. boosted its stake in shares of Precigen by 29.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock worth $30,000 after buying an additional 5,915 shares during the last quarter. Apella Capital LLC bought a new stake in shares of Precigen in the first quarter worth $40,000. Boothbay Fund Management LLC purchased a new stake in Precigen during the fourth quarter valued at $35,000. Finally, Voya Investment Management LLC increased its position in Precigen by 142.9% during the first quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 21,633 shares during the last quarter. Institutional investors own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.